U.S. Markets closed
  • S&P 500

    3,911.74
    +116.01 (+3.06%)
     
  • Dow 30

    31,500.68
    +823.32 (+2.68%)
     
  • Nasdaq

    11,607.62
    +375.43 (+3.34%)
     
  • Russell 2000

    1,765.74
    +54.06 (+3.16%)
     
  • Crude Oil

    107.06
    +2.79 (+2.68%)
     
  • Gold

    1,828.10
    -1.70 (-0.09%)
     
  • Silver

    21.13
    +0.09 (+0.42%)
     
  • EUR/USD

    1.0559
    +0.0034 (+0.3273%)
     
  • 10-Yr Bond

    3.1250
    +0.0570 (+1.86%)
     
  • Vix

    27.23
    -1.82 (-6.27%)
     
  • GBP/USD

    1.2270
    +0.0009 (+0.0736%)
     
  • USD/JPY

    135.2100
    +0.2770 (+0.2053%)
     
  • BTC-USD

    21,263.93
    +99.10 (+0.47%)
     
  • CMC Crypto 200

    462.12
    +8.22 (+1.81%)
     
  • FTSE 100

    7,208.81
    +188.36 (+2.68%)
     
  • Nikkei 225

    26,491.97
    +320.72 (+1.23%)
     

Enveric Biosciences Files Provisional Patent for Cannabinoid + Celecoxib Conjugate EV104 after Successful Synthesis

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

By Alan Hatfield

Neuroscience company Enveric Biosciences (NASDAQ: ENVB) announced the creation of EV104a and EV104b for the potential treatment of Osteoarthritis and other pain indications.

Known as the most common form of arthritis, osteoarthritis is also a leading cause of disability. Enveric’s EV104 program entered pre-clinical testing to advance into clinical development with the hope of offering better options for patients living with pain. It aims to create a new treatment with improved tolerability, decreased toxicity, fewer side effects, and enhanced long-term efficacy.

The treatment paradigm for OA, as reflected in a recent review “Future Directions for the Management of Pain in Osteoarthritis” by Nidhi Sofat, is largely unsatisfactory and based on alleviating pain using NSAIDs and other pharmacotherapies or intra-articular injection of corticosteroids, or hyaluronic acid. Newer therapeutic alternatives, including combination treatments, are needed for optimal control of symptoms.

“CBD presents a unique pharmacodynamic profile and exerts joint analgesic and anti-inflammatory effects on different pain types including neuropathic pain, inflammatory, osteoarthritis and others. In the case of Osteoarthritis (OA) which is a degenerative joint disease, CBD’s treatment benefits have been demonstrated in several models by showing reduction in joint swelling, limb posture scores, synovial membrane thickening and pain,” explained Bob Dagher. MD, Enveric’s Chief Medical Officer.

He continued, “The mechanism of action of celecoxib, different from CBD, is attributed to the inhibition of COX-2, which is responsible for prostaglandin synthesis, an integral part of the pain and inflammation pathways. CBD with celecoxib conjugation offers the opportunity for augmenting the treatment benefit by having potential superior efficacy and lower side effects, by administering lower amounts of the individual components of the conjugate.”

The company, which develops next-generation, psychedelic-inspired mental health, and oncology treatments, recently licensed an Innovative Platform technology from Diverse Biotech that led to the successful synthesis of these two new chemical entity conjugates of cannabidiol (CBD) linked to celecoxib.

The EV104 conjugates are protected by a recently filed provisional United States patent application claiming the compositions, methods of synthesis, and methods of treatment for inflammatory medical conditions.

Enveric has confirmed the stability of the molecules and the robustness of the manufacturing method. Pre-clinical in vitro testing and characterization of these molecules is underway.